Flagship Ventures Opportunities Fund I General Partner LLC's Net Worth

-$142 Million

Estimate Recalculated Jun 28, 2024 03:09PM EST

Who is Flagship Ventures Opportunities Fund I General Partner LLC?

Flagship Ventures Opportunities Fund I General Partner LLC does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Kaleido Biosciences, Inc., Foghorn Therapeutics Inc., Evelo Biosciences, Inc., Rubius Therapeutics, Inc., and Axcella Health Inc..

SEC CIK

Flagship Ventures Opportunities Fund I General Partner LLC's CIK is 0001725004

Past Insider Trading and Trends

2019 was Flagship Ventures Opportunities Fund I General Partner LLC's most active year for acquiring shares with 24 total transactions. Flagship Ventures Opportunities Fund I General Partner LLC's most active month to acquire stocks was the month of April. 2019 was Flagship Ventures Opportunities Fund I General Partner LLC's most active year for disposing of shares, totalling 20 transactions. Flagship Ventures Opportunities Fund I General Partner LLC's most active month to dispose stocks was the month of April. 2022 saw Flagship Ventures Opportunities Fund I General Partner LLC paying a total of $69,099,363.15 for 44,100,390 shares, this is the most they've acquired in one year. In 2018 Flagship Ventures Opportunities Fund I General Partner LLC cashed out on 59,643,740 shares for a total of $0.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Kaleido Biosciences, Inc. (KLDO) Snapshot price: $0.000001

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+4.14%
215K
$11.50
$2,472,500.00
5.41M
Feb 8
Form 4
+62.67%
2M
$7.50
$15,000,000.00
5.19M
Jun 4
Form 4
+47.12%
12M
$15.00
$13,999,995.00
37.48M
Mar 4
Form 3
—
0
—
—
0
No matching records found

Foghorn Therapeutics Inc. (FHTX) Snapshot price: $3.19

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
∞
12.67M
$16.00
—
12.67M
Oct 27
Form 3
—
0
—
—
0
No matching records found

Axcella Health Inc. (AXLA) Snapshot price: $0.4009

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+79.47%
10.38M
$1.64
$17,029,366.40
23.45M
Oct 13
Form 4
+72.21%
6.32M
$1.91
$12,069,998.61
15.07M
Mar 16
Form 4
+76.74%
3.8M
$4.75
$18,050,000.00
8.75M
May 18
Form 4
+46.30%
6.03M
$20.00
—
19.07M
May 13
Form 3
—
0
—
—
0
No matching records found

Evelo Biosciences, Inc. (EVLO) Snapshot price: $0.04

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+288.55%
27.4M
$1.46
$39,999,998.14
36.89M
May 27
Form 4
+1.39%
130K
$15.00
$1,950,000.00
9.49M
Feb 2
Form 4
+99.33%
4.67M
$3.75
$17,499,997.50
9.36M
Jun 29
Form 4
+447.55%
14.9M
$16.00
$4,500,000.00
18.23M
May 11
Form 3
—
0
—
—
0
No matching records found

Rubius Therapeutics, Inc. (RUBY) Snapshot price: $0.053

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+0.89%
210K
$29.00
$6,090,000.00
23.89M
Mar 19
No matching records found